Takeda Pharmaceutical Company Limited (NYSE:TAK - Get Free Report) shares saw strong trading volume on Wednesday . 853,714 shares traded hands during trading, a decline of 47% from the previous session's volume of 1,609,208 shares.The stock last traded at $13.23 and had previously closed at $13.35.
Takeda Pharmaceutical Price Performance
The company has a fifty day moving average price of $13.51 and a two-hundred day moving average price of $13.89. The company has a debt-to-equity ratio of 0.64, a quick ratio of 0.77 and a current ratio of 1.28. The company has a market cap of $42.06 billion, a P/E ratio of 22.79, a PEG ratio of 0.25 and a beta of 0.51.
Institutional Investors Weigh In On Takeda Pharmaceutical
A number of institutional investors and hedge funds have recently made changes to their positions in TAK. Millennium Management LLC increased its position in Takeda Pharmaceutical by 87.1% during the second quarter. Millennium Management LLC now owns 4,346,151 shares of the company's stock worth $56,239,000 after buying an additional 2,023,707 shares during the last quarter. FMR LLC raised its stake in Takeda Pharmaceutical by 10.9% in the 3rd quarter. FMR LLC now owns 2,908,918 shares of the company's stock valued at $41,365,000 after acquiring an additional 286,052 shares during the period. Stifel Financial Corp lifted its holdings in Takeda Pharmaceutical by 103.9% during the 3rd quarter. Stifel Financial Corp now owns 440,666 shares of the company's stock valued at $6,266,000 after purchasing an additional 224,594 shares during the last quarter. Summit Global Investments boosted its position in Takeda Pharmaceutical by 86.0% during the third quarter. Summit Global Investments now owns 415,558 shares of the company's stock worth $5,909,000 after purchasing an additional 192,143 shares during the period. Finally, Van ECK Associates Corp increased its holdings in shares of Takeda Pharmaceutical by 6.6% in the third quarter. Van ECK Associates Corp now owns 2,175,236 shares of the company's stock valued at $30,149,000 after purchasing an additional 134,407 shares during the last quarter. Institutional investors own 9.17% of the company's stock.
About Takeda Pharmaceutical
(
Get Free Report)
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.
Further Reading
Before you consider Takeda Pharmaceutical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Takeda Pharmaceutical wasn't on the list.
While Takeda Pharmaceutical currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
